Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance

被引:123
作者
Kestin, Larry [1 ]
Grills, Inga [2 ]
Guckenberger, Matthias [3 ]
Belderbos, Jose [4 ]
Hope, Andrew J. [5 ]
Werner-Wasik, Maria [6 ]
Sonke, Jan-Jakob [4 ]
Bissonnette, Jean-Pierre [5 ]
Xiao, Ying [6 ]
Yan, Di [2 ]
机构
[1] 21st Century Oncol Michigan Healthcare Profess, Farmington Hills, MI 48334 USA
[2] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI USA
[3] Univ Wurzburg, Dept Radiat Oncol, Wurzburg, Germany
[4] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[5] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5S 1A1, Canada
[6] Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Philadelphia, PA 19107 USA
关键词
Lung cancer; Stereotactic body radiotherapy; Image-guided radiotherapy; Dose response; RADIATION-THERAPY; CANCER; CARCINOMA;
D O I
10.1016/j.radonc.2014.02.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine potential dose-response relationships with various non-small-cell lung cancer (NSCLC) SBRT fractionation regimens delivered with online CT-based image guidance. Methods: 505 tumors in 483 patients with clinical stage T1-T2NO NSCLC were treated with SBRT using on-line cone-beam-CT-based image guidance at 5 institutions (1998-2010). Median maximum tumor dimension was 2.6 cm (range 0.9-8.5 cm). Dose fractionation prescription was according to each institution's protocol with the most common schedules of 18-20 GyX3, 12 GyX4, 12 GyX5, 12.5 GyX3, 7.5 GyX8 (median = 54 Gy, 3 fractions). Median prescription (Rx) BED10= 132 Gy (50.4-180). Median values (Gy) of 3D planned doses for BED10 were GTV(min) = 164.1, GTV(mean) = 188.4, GTV(max) = 205.9, PTVmin = 113.9, PTV 099 = 123.9, PTV mean mean = 164.7, PTV D1 = 197.3, PTV., = 210.7. Mean follow-up = 1.6 years. Results: 26 cases (5%) had local recurrence (LR) for a 2-year rate of 6% and 3-year rate of 9%. All BED10 GTV&PTV endpoints were associated with LR as continuous variables on univariate analysis (p < 0.05). Rx and PTV mean mean dose appeared to have the highest correlation with LR with area under ROC curve of 0.69 and 0.65 respectively and optimal cut points of 105 and 125 Gy, respectively. 2-year LR was 4% for PTV (mean) > 125 vs 17% for <125 Gy (p <0.01) with sensitivity = 84% and specificity = 57% for predicting LR. 2-year LR for Rx BED10 > 105 was 4% vs 15% for <105 Gy (p < 0.01). Longer treatment duration (>= 11 elapsed days) demonstrated a 2-year LR of 14% vs 4% for <= 10 days (p <0.01). GTV size was associated with LR on univariate analysis as a continuous variable (p = 0.02) with 2-year LR = 3% for <2.7 cm vs 9% for ?-.2.7 cm (p = 0.03). BED10 (p = 0.01) and elapsed days during RT (p = 0.05) were independent predictors on multivariate analysis as continuous variables. Conclusions: There is a substantial dose-response relationship for local control of NSCLC following image guided SBRT with optimal PTV mean mean BED10 > 125 Gy. Shorter treatment duration was also associated with better local control in this dataset. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:499 / 504
页数:6
相关论文
共 16 条
  • [1] Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Wennberg, Berit
    Gagliardi, Giovanna
    Lax, Ingmar
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3290 - 3296
  • [2] Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer
    Chang, Joe Y.
    Liu, Hui
    Balter, Peter
    Komaki, Ritsuko
    Liao, Zhongxing
    Welsh, James
    Mehran, Reza J.
    Roth, Jack A.
    Swisher, Stephen G.
    [J]. RADIATION ONCOLOGY, 2012, 7
  • [3] RADIATION-THERAPY IN THE MANAGEMENT OF MEDICALLY INOPERABLE CARCINOMA OF THE LUNG - RESULTS AND IMPLICATIONS FOR FUTURE TREATMENT STRATEGIES
    DOSORETZ, DE
    KATIN, MJ
    BLITZER, PH
    RUBENSTEIN, JH
    SALENIUS, S
    RASHID, M
    DOSANI, RA
    MESTAS, G
    SIEGEL, AD
    CHADHA, TT
    CHANDRAHASA, T
    HANNAN, SE
    BHAT, SB
    METKE, MP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (01): : 3 - 9
  • [4] STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY
    Fakiris, Achilles J.
    McGarry, Ronald C.
    Yiannoutsos, Constantin T.
    Papiez, Lech
    Williams, Mark
    Henderson, Mark A.
    Timmerman, Robert
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 677 - 682
  • [5] DOSIMETRIC IMPACT OF ONLINE CORRECTION VIA CONE-BEAM CT-BASED IMAGE GUIDANCE FOR STEREOTACTIC LUNG RADIOTHERAPY
    Galerani, Ana Paula
    Grills, Inga
    Hugo, Geoffrey
    Kestin, Larry
    Mohammed, Nasiruddin
    Chao, K. Kenneth
    Suen, Andrew
    Martinez, Alvaro
    Yan, Di
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (05): : 1571 - 1578
  • [6] Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer
    Grills, Inga S.
    Mangona, Victor S.
    Welsh, Robert
    Chmielewski, Gary
    McInerney, Erika
    Martin, Shannon
    Wloch, Jennifer
    Ye, Hong
    Kestin, Larry L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 928 - 935
  • [7] DOSE-RESPONSE RELATIONSHIP FOR IMAGE-GUIDED STEREOTACTIC BODY RADIOTHERAPY OF PULMONARY TUMORS: RELEVANCE OF 4D DOSE CALCULATION
    Guckenberger, Matthias
    Wulf, Joern
    Mueller, Gerd
    Krieger, Thomas
    Baier, Kurt
    Gabor, Manuela
    Richter, Anne
    Wilbert, Juergen
    Flentje, Michael
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (01): : 47 - 54
  • [8] Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
    Nagata, Y
    Takayama, K
    Matsuo, Y
    Norihisa, Y
    Mizowaki, T
    Sakamoto, T
    Sakamoto, M
    Mitsumori, M
    Shibuya, K
    Araki, N
    Yano, S
    Hiraoka, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1427 - 1431
  • [9] Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy
    Onimaru, Rikiya
    Fujino, Masaharu
    Yamazaki, Koichi
    Onodera, Yuya
    Taguchi, Hiroshi
    Katoh, Norio
    Hommura, Fumihiro
    Oizumi, Satoshi
    Nishimura, Masaharu
    Shirato, Hiroki
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (02): : 374 - 381
  • [10] Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study
    Onishi, Hiroshi
    Shirato, Hiroki
    Nagata, Yasushi
    Hiraoka, Masahiro
    Fujino, Masaharu
    Gomi, Kotaro
    Niibe, Yuzuru
    Karasawa, Katsuyuki
    Hayakawa, Kazushige
    Takai, Yoshihiro
    Kimura, Tomoki
    Takeda, Atsuya
    Ouchi, Atsushi
    Hareyama, Masato
    Kokubo, Masaki
    Hara, Ryusuke
    Itami, Jun
    Yamada, Kazunari
    Araki, Tsutomu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : S94 - S100